Peregrine Pharmaceuticals Inc (PPHM)

0.70
0.03 3.50
NASDAQ : Health Care
Prev Close 0.73
Open 0.71
Day Low/High 0.70 / 0.72
52 Wk Low/High 0.29 / 1.32
Volume 1.73M
Avg Volume 3.91M
Exchange NASDAQ
Shares Outstanding 297.71M
Market Cap 211.37M
EPS -0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Peregrine Pharmaceuticals' Series E Preferred Stock Yield Pushes Past 13%

Peregrine Pharmaceuticals' Series E Preferred Stock Yield Pushes Past 13%

In trading on Wednesday, shares of Peregrine Pharmaceuticals Inc.'s 10.50% Series E Convertible Preferred Stock were yielding above the 13% mark based on its quarterly dividend (annualized to $2.625), with shares changing hands as low as $20.16 on the day. This compares to an average yield of 11.31% in the "Biotechnology" preferred stock category, according to Preferred Stock Channel.

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

TheStreet's biotech columnist offers his own report card on biotech stocks.

Peregrine Pharmaceuticals' Series E Preferred Stock Shares Cross 11.5% Yield Mark

Peregrine Pharmaceuticals' Series E Preferred Stock Shares Cross 11.5% Yield Mark

In trading on Tuesday, shares of Peregrine Pharmaceuticals Inc.'s 10.50% Series E Convertible Preferred Stock were yielding above the 11.5% mark based on its quarterly dividend (annualized to $2.625), with shares changing hands as low as $22.80 on the day. This compares to an average yield of 9.98% in the "Biotechnology" preferred stock category, according to Preferred Stock Channel.

Peregrine Pharmaceuticals Provides Update On Oral Presentation Of Top-Line Data From Phase III SUNRISE Trial Of Bavituximab At European Society For Medical Oncology (ESMO) 2016 Congress

Peregrine Pharmaceuticals Provides Update On Oral Presentation Of Top-Line Data From Phase III SUNRISE Trial Of Bavituximab At European Society For Medical Oncology (ESMO) 2016 Congress

Ongoing Biomarker Analysis Has Identified a Biomarker that is Associated with a Statistically Significant Improvement in Overall Survival for Patients Receiving the Bavituximab Combination

National Comprehensive Cancer Network (NCCN) Awards Three Grants For Combination Studies Of Peregrine Pharmaceuticals' Bavituximab In Multiple Cancers

National Comprehensive Cancer Network (NCCN) Awards Three Grants For Combination Studies Of Peregrine Pharmaceuticals' Bavituximab In Multiple Cancers

Peregrine's Novel PS-Targeting Immuno-Oncology (I-O) Agent to be Combined with Immunotherapy and Traditional Cancer Treatments in Studies Focused on Glioblastoma, Head and Neck Cancer and Hepatocellular Carcinoma

Avid Bioservices To Participate In Cambridge Healthtech Institute's (CHI) 8th Annual The Bioprocessing Summit

Avid Bioservices To Participate In Cambridge Healthtech Institute's (CHI) 8th Annual The Bioprocessing Summit

Company Selected for Presentation and Panel Participation; Will Showcase Industry-Leading Contract Manufacturing Capabilities Spanning Early Stage Development to Commercialization

Peregrine Pharmaceuticals' Series E Preferred Stock Shares Cross 15% Yield Mark

Peregrine Pharmaceuticals' Series E Preferred Stock Shares Cross 15% Yield Mark

In trading on Thursday, shares of Peregrine Pharmaceuticals Inc.'s 10.50% Series E Convertible Preferred Stock were yielding above the 15% mark based on its quarterly dividend (annualized to $2.625), with shares changing hands as low as $17.22 on the day. As of last close, PPHMP was trading at a 29.60% discount to its liquidation preference amount.

Peregrine Pharmaceuticals' Series E Preferred Stock Shares Cross 15% Yield Mark

Peregrine Pharmaceuticals' Series E Preferred Stock Shares Cross 15% Yield Mark

In trading on Wednesday, shares of Peregrine Pharmaceuticals Inc.'s 10.50% Series E Convertible Preferred Stock were yielding above the 15% mark based on its quarterly dividend (annualized to $2.625), with shares changing hands as low as $17.15 on the day. As of last close, PPHMP was trading at a 29.00% discount to its liquidation preference amount.